
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
Therapeutic Management of Immune Thrombocytopenia
Case: A 44-year-old woman presenting with reddish-purple rash on lower legs
February 2017
February 2018
